147 related articles for article (PubMed ID: 8645089)
1. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.
Kariya N; Hayashi K; Hoshino H; Tanaka Y; Koirala TR; Ohara N; Miyamoto K; Akagi T
Arch Virol; 1996; 141(3-4):471-80. PubMed ID: 8645089
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel neutralization epitope on envelope gp46 antigen of human T-cell-leukemia virus-type-II (HTLV-II).
Tanaka Y; Tanaka R; Hoshino H
Int J Cancer; 1994 Dec; 59(5):655-60. PubMed ID: 7525496
[TBL] [Abstract][Full Text] [Related]
3. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
[TBL] [Abstract][Full Text] [Related]
4. [Production of HTLV-II env protein and its suppressive effect on infection].
Kawamura N
Hokkaido Igaku Zasshi; 1995 Jul; 70(4):635-47. PubMed ID: 7590608
[TBL] [Abstract][Full Text] [Related]
5. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
[TBL] [Abstract][Full Text] [Related]
7. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
8. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
9. HTLV-II-specific antisera raised in rabbits immunized with a synthetic peptide of HTLV-II envelope protein.
Hayashi K; Ohara N; Fujiwara K; Jeon HJ; Koirala TR; Takahashi K; Akagi T; Tomita N; Miyamoto K
Virchows Arch B Cell Pathol Incl Mol Pathol; 1992; 63(1):37-41. PubMed ID: 1362020
[TBL] [Abstract][Full Text] [Related]
10. Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.
Tanaka Y; Tanaka R; Terada E; Koyanagi Y; Miyano-Kurosaki N; Yamamoto N; Baba E; Nakamura M; Shida H
J Virol; 1994 Oct; 68(10):6323-31. PubMed ID: 8083972
[TBL] [Abstract][Full Text] [Related]
11. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell-free human T-cell leukemia virus type 1 infection at a postbinding step by the synthetic peptide derived from an ectodomain of the gp21 transmembrane glycoprotein.
Jinno A; Haraguchi Y; Shiraki H; Hoshino H
J Virol; 1999 Nov; 73(11):9683-9. PubMed ID: 10516085
[TBL] [Abstract][Full Text] [Related]
13. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
14. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing human monoclonal antibodies to conformational epitopes of human T-cell lymphotropic virus type 1 and 2 gp46.
Hadlock KG; Rowe J; Perkins S; Bradshaw P; Song GY; Cheng C; Yang J; Gascon R; Halmos J; Rehman SM; McGrath MS; Foung SK
J Virol; 1997 Aug; 71(8):5828-40. PubMed ID: 9223472
[TBL] [Abstract][Full Text] [Related]
17. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
18. Complete nucleotide sequence of HTLV-II isolate NRA: comparison of envelope sequence variation of HTLV-II isolates from U.S. blood donors and U.S. and Italian i.v. drug users.
Lee H; Idler KB; Swanson P; Aparicio JJ; Chin KK; Lax JP; Nguyen M; Mann T; Leckie G; Zanetti A
Virology; 1993 Sep; 196(1):57-69. PubMed ID: 8356807
[TBL] [Abstract][Full Text] [Related]
19. Immunoelectron microscopic study of HTLV-II-producing cells with an anti-envelope gp46 monoclonal antibody.
Ohara N; Hayashi K; Miyamoto K; Takahashi K; Ohtsuki Y; Akagi T
Arch Virol; 1995; 140(7):1291-5. PubMed ID: 7646360
[TBL] [Abstract][Full Text] [Related]
20. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
